Kristen Fortney is the co-founder and CEO of BioAge Labs, a clinical-stage biotechnology company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human longevity. By targeting these pathways with a large and mechanistically diverse portfolio of drugs, BioAge is unlocking opportunities to treat and prevent diseases of aging in entirely new ways. Fortney’s scientific background is in aging biology and bioinformatics.
Previously
Scientists are deeply engaged in efforts to slow aging and eliminate age-related diseases by editing genes, reprogramming cells, and developing novel molecular therapeutics. A...